NCT05256290: An ongoing trial by Black Diamond Therapeutics, Inc.
This trial is ongoing. It must report results 10 months, 3 weeks from now.
Full data
| Full entry on ClinicalTrials.gov | NCT05256290 |
|---|---|
| Title | A Phase 1/2 Study to Assess BDTX-1535, an Oral EGFR Inhibitor, in Patients With Glioblastoma or Non-Small Cell Lung Cancer |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | March 31, 2022 |
| Completion date | Nov. 3, 2025 |
| Required reporting date | Nov. 3, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |